Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 79.45% is in line with its 5-year average of 80.66%, near the low end of its 5-year range (78.47%–82.34%).
0.04% above its 12-month average of 79.42%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 78.47%.
GROSS MARGIN
79.45%
GROSS MARGIN AVG TTM
79.42%
GROSS MARGIN AVG 3Y
80.13%
GROSS MARGIN AVG 5Y
80.66%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.04%
CURRENT VS 3Y AVG
-0.85%
CURRENT VS 5Y AVG
-1.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+92.00%
vs the sector median at left
Treace Medical Concepts, Inc.
Market Cap
$267.28M
Gross Margin
79.45%
TTM Avg
79.42%
3Y Avg
80.13%
5Y Avg
80.66%
Market Cap
$270.34M
Gross Margin
92.82%
TTM Avg
94.13%
3Y Avg
92.76%
5Y Avg
92.02%
Market Cap
$264.73M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
-1258.31%
5Y Avg
-887.92%
Market Cap
$264.93M
Gross Margin
93.41%
TTM Avg
92.41%
3Y Avg
88.66%
5Y Avg
85.93%
Market Cap
$270.68M
Gross Margin
0.00%
TTM Avg
-131.21%
3Y Avg
-60.86%
5Y Avg
-7.69%
Market Cap
$271.58M
Gross Margin
-94.12%
TTM Avg
-431.85%
3Y Avg
-231.35%
5Y Avg
-189.25%
Market Cap
$272.01M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$263.32M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Treace Medical Concepts, Inc. (TMCI) | $267.28M | 79.45% | 79.42% | 80.13% | 80.66% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.34M | 92.82% | 94.13% | 92.76% | 92.02% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.73M | 0.00% | 0.00% | -1258.31% | -887.92% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.93M | 93.41% | 92.41% | 88.66% | 85.93% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $270.68M | 0.00% | -131.21% | -60.86% | -7.69% |
| Fate Therapeutics, Inc. (FATE)vs › | $271.58M | -94.12% | -431.85% | -231.35% | -189.25% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $272.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $263.32M | 0.00% | 0.00% | 0.00% | 0.00% |
| Scribe Therapeutics Inc. (SCTX)vs › | $272.34M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $271.54M | 85.79% | 85.31% | 84.59% | 70.69% |
Gross Margin
79.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 78.47% |
| 2026-03-31 | 79.26% |
| 2025-12-31 | 80.62% |
| 2025-09-30 | 79.07% |
| 2025-06-30 | 79.67% |
| 2025-03-31 | 79.69% |
| 2024-12-31 | 80.74% |
| 2024-09-30 | 80.14% |
| 2024-06-30 | 80.25% |
| 2024-03-31 | 80.19% |
| 2023-12-31 | 81.56% |
| 2023-09-30 | 80.38% |
| 2023-06-30 | 81.71% |
| 2023-03-31 | 80.95% |
| 2022-12-31 | 80.43% |
| 2022-09-30 | 81.58% |
| 2022-06-30 | 82.34% |
| 2022-03-31 | 82.34% |
| 2021-12-31 | 81.14% |
| 2021-09-30 | 80.35% |
| 2021-06-30 | 80.90% |
| 2021-03-31 | 82.22% |
| 2020-12-31 | 78.91% |
| 2020-09-30 | 79.59% |
| 2020-06-30 | 73.06% |
| 2020-03-31 | 78.78% |
